<HashMap><database>biostudies-literature</database><scores/><additional><submitter>McCarthy C</submitter><funding>NHLBI NIH HHS</funding><pagination>207-219</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10037558</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>81(3)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Few data exist regarding the implementation of high-sensitivity cardiac troponin (hs-cTn) assays in the United States since their approval.&lt;h4>Objectives&lt;/h4>This study sought to explore trends in hs-cTn assay implementation over time and assess the association of their use with in-hospital cardiac testing and outcomes.&lt;h4>Methods&lt;/h4>The study examined trends in implementation of hs-cTn assays among participating hospitals in the National Cardiovascular Data Registry Chest Pain-MI [Myocardial Infarction] Registry from January 1, 2019 through September 30, 2021. Associations among hs-cTn use, use of in-hospital diagnostic imaging, and patient outcomes were assessed using generalized estimating equation models with logistic or gamma distributions.&lt;h4>Results&lt;/h4>Among 550</pubmed_abstract><journal>Journal of the American College of Cardiology</journal><pubmed_title>Implementation of High-Sensitivity Cardiac Troponin Assays in the United States.</pubmed_title><pmcid>PMC10037558</pmcid><funding_grant_id>K23 HL150315</funding_grant_id><funding_grant_id>T32 HL094301</funding_grant_id><pubmed_authors>Wang TY</pubmed_authors><pubmed_authors>de Lemos JA</pubmed_authors><pubmed_authors>Jaffe AS</pubmed_authors><pubmed_authors>Sandoval Y</pubmed_authors><pubmed_authors>Januzzi JL</pubmed_authors><pubmed_authors>Raber I</pubmed_authors><pubmed_authors>Li S</pubmed_authors><pubmed_authors>Wasfy JH</pubmed_authors><pubmed_authors>Apple FS</pubmed_authors><pubmed_authors>Newby LK</pubmed_authors><pubmed_authors>Kontos MC</pubmed_authors><pubmed_authors>Smilowitz NR</pubmed_authors><pubmed_authors>Pandey A</pubmed_authors><pubmed_authors>Daniels LB</pubmed_authors><pubmed_authors>McCarthy C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Implementation of High-Sensitivity Cardiac Troponin Assays in the United States.</name><description>&lt;h4>Background&lt;/h4>Few data exist regarding the implementation of high-sensitivity cardiac troponin (hs-cTn) assays in the United States since their approval.&lt;h4>Objectives&lt;/h4>This study sought to explore trends in hs-cTn assay implementation over time and assess the association of their use with in-hospital cardiac testing and outcomes.&lt;h4>Methods&lt;/h4>The study examined trends in implementation of hs-cTn assays among participating hospitals in the National Cardiovascular Data Registry Chest Pain-MI [Myocardial Infarction] Registry from January 1, 2019 through September 30, 2021. Associations among hs-cTn use, use of in-hospital diagnostic imaging, and patient outcomes were assessed using generalized estimating equation models with logistic or gamma distributions.&lt;h4>Results&lt;/h4>Among 550</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan</publication><modification>2025-04-03T23:49:51.829Z</modification><creation>2025-04-03T23:49:51.829Z</creation></dates><accession>S-EPMC10037558</accession><cross_references><pubmed>36328155</pubmed><doi>10.1016/j.jacc.2022.10.017</doi></cross_references></HashMap>